(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1472279

吸入式一酸化窒素市場：用途別：世界の機会分析と産業予測、2023～2032年

Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日
ページ情報
英文 179 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
吸入式一酸化窒素市場：用途別：世界の機会分析と産業予測、2023～2032年
出版日: 2024年03月01日
発行: Allied Market Research
ページ情報: 英文 179 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の吸入式一酸化窒素市場は2022年に8億米ドルと評価され、2023～2032年にかけてCAGR 7.7%で成長し、2032年には16億米ドルに達すると予測される

吸入式一酸化窒素は、新生児の低酸素性呼吸不全や持続性肺高血圧症の管理・治療に用いられる治療ガスです。吸入式一酸化窒素は選択的肺血管拡大薬であり、肺のよく換気された領域への血流を改善し、換気と灌流のマッチングを改善し、肺高血圧を軽減します。主要作用機序は、平滑筋細胞におけるグアニル酸シクラーゼの活性化であり、環状グアノシン一リン酸（cGMP）の増加とそれに続く血管拡大をもたらします。

Inhaled Nitric Oxide Market-IMG1

吸入式一酸化窒素市場の成長は、新生児低酸素性呼吸不全と慢性閉塞性肺疾患の有病率の上昇に対する吸入式一酸化窒素の高い採用に起因しています。新生児低酸素性呼吸不全に対する吸入式一酸化窒素の高い採用率は、吸入式一酸化窒素市場の成長を促進する主要な要因として際立っています。近年、吸入式一酸化窒素は、新生児医療の現場において、特に低酸素状態による呼吸困難を経験している乳児に対する重要な治療介入として浮上しています。例えば、米国食品医薬品局は1999年にINOmaxを、2019年にGenosylを、肺高血圧の臨床的または心エコー的徴候を伴う低酸素性呼吸不全の正期産児と臨月産児（妊娠34週超）に対して承認し、酸素化を改善し、体外膜酸素化のリスクを低下させています。

新生児は子宮外生活への適応においてしばしば課題に直面し、低酸素性呼吸不全はこの過渡期における重大な懸念です。血管拡大作用を有する吸入式一酸化窒素は、肺血管系に選択的に作用し、肺血管を拡大して酸素供給を改善し、肺高血圧を軽減します。潜在的な全身的副作用を最小限に抑えながら酸素供給を増強するその有効性は、医療専門家の間で広く受け入れられています。

早産や先天性障害などの要因による新生児低酸素性呼吸不全の有病率の増加は、効果的な治療オプションに対する需要の急増につながり、吸入式一酸化窒素の採用をさらに促進しています。さらに、低酸素誘発性合併症の予防や軽減における吸入式一酸化窒素の利点に関する医療提供者の意識の高まりは、新生児集中治療プロトコールへの吸入式一酸化窒素の広範な組み込みに寄与しています。したがって、新生児低酸素性呼吸不全に対する吸入式一酸化窒素の高い採用率は、吸入式一酸化窒素の成長を促進すると予想されます。

さらに、慢性閉塞性肺疾患の有病率の上昇が市場の成長を促進すると予想されます。慢性閉塞性肺疾患は、主にタバコの煙に含まれるような有害な粒子やガスに長期間さらされることによって引き起こされる進行性の衰弱性呼吸器疾患で、世界的に憂慮すべきレベルに達しています。例えば、国立医療図書館による2022年の報告によると、慢性閉塞性肺疾患（COPD）の世界的有病率は40歳以上で10.1％であると報告されています。COPDの罹患率が上昇を続ける中、罹患者の症状を緩和し、全体的な生活の質を高めることができる効果的な治療介入が緊急に求められています。吸入式一酸化窒素の採用は、COPDを含む呼吸器疾患の管理におけるその可能性により急増しています。一酸化窒素の血管拡大作用と抗炎症作用は、肺機能を改善する有望な候補となります。したがって、慢性閉塞性肺疾患の有病率の上昇は、市場の成長に大きく寄与すると予想されます。

吸入式一酸化窒素市場は、用途と地域によって区分されます。用途別では、新生児呼吸器治療、慢性閉塞性肺疾患（COPD）、急性呼吸窮迫症候群（ARDS）、その他に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、その他の欧州地域）、アジア太平洋（日本、オーストラリア、その他のアジア太平洋）、ラテンアメリカ地域（中南米、その他中東・アフリカ）に分けて分析しています。

利害関係者にとっての主要メリット

  • 当レポートは、2022～2032年までの吸入式一酸化窒素市場分析の市場セグメント、現在の動向、推定・動向、力学の定量分析を提供し、優勢な吸入式一酸化窒素市場機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を記載しています。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるように、バイヤーとサプライヤーの潜在力を強調します。
  • 吸入式一酸化窒素の市場セグメンテーションの詳細な分析は、市場機会を決定するのに役立ちます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場参入企業のポジショニングはベンチマーキングを容易にし、市場参入企業の現在のポジションを明確に理解することができます。
  • この調査レポートは、地域別と世界の吸入式一酸化窒素市場動向、主要企業、市場セグメント、用途セグメント、市場成長戦略の分析を含んでいます。

本レポートで可能なレポートカスタマイズ（追加費用とスケジュールがあります。）

  • 国、地域、世界レベルでの患者/疫学データ
  • 規制ガイドライン
  • クライアントの関心に応じた追加企業プロファイル
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • SWOT分析

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主要調査結果
    • 影響要因
    • 主要投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 乳幼児や新生児の肺疾患管理のための吸入式一酸化窒素の高い採用率
      • 呼吸器疾患の有病率の上昇
      • 医療インフラの進歩
    • 抑制要因
      • 吸入式一酸化窒素の高コスト
    • 機会
      • 盛んな吸入式一酸化窒素の研究開発活動
  • 市場シェア分析

第4章 吸入式一酸化窒素市場：用途別

  • 概要
  • 新生児呼吸器治療
  • 慢性閉塞性肺疾患
  • 急性呼吸窮迫症候群
  • その他

第5章 酸化窒素吸入市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • その他
  • アジア太平洋
    • 日本
    • オーストラリア
    • その他
  • ラテンアメリカ
    • ラテンアメリカ
    • 中東・アフリカ

第6章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第7章 企業プロファイル

  • Air Liquide S.A.
  • Linde PLC
  • Mallinckrodt plc
  • Vero Biotech LLC
  • SOL Group
  • Air Water Inc.
  • Chemix Specialty Gases and Equipment
  • Nippon Sanso Holdings Corporation
  • Chengdu Taiyu Industrial Gases Co., Ltd.
  • Sichuan Salman Chemical Products Co., Ltd
図表

LIST OF TABLES

  • TABLE 01. GLOBAL INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 02. INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. INHALED NITRIC OXIDE MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. INHALED NITRIC OXIDE MARKET FOR ACUTE RESPIRATORY DISTRESS SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. INHALED NITRIC OXIDE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. INHALED NITRIC OXIDE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 08. NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 09. U.S. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 10. CANADA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. MEXICO INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. EUROPE INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. GERMANY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. FRANCE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. UK INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. ITALY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. REST OF EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. JAPAN INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. AUSTRALIA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. REST OF ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. LAMEA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. LAMEA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 26. LATIN AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. AIR LIQUIDE S.A.: KEY EXECUTIVES
  • TABLE 29. AIR LIQUIDE S.A.: COMPANY SNAPSHOT
  • TABLE 30. AIR LIQUIDE S.A.: PRODUCT SEGMENTS
  • TABLE 31. AIR LIQUIDE S.A.: PRODUCT PORTFOLIO
  • TABLE 32. LINDE PLC: KEY EXECUTIVES
  • TABLE 33. LINDE PLC: COMPANY SNAPSHOT
  • TABLE 34. LINDE PLC: PRODUCT SEGMENTS
  • TABLE 35. LINDE PLC: PRODUCT PORTFOLIO
  • TABLE 36. LINDE PLC: KEY STRATERGIES
  • TABLE 37. MALLINCKRODT PLC: KEY EXECUTIVES
  • TABLE 38. MALLINCKRODT PLC: COMPANY SNAPSHOT
  • TABLE 39. MALLINCKRODT PLC: PRODUCT SEGMENTS
  • TABLE 40. MALLINCKRODT PLC: PRODUCT PORTFOLIO
  • TABLE 41. VERO BIOTECH LLC: KEY EXECUTIVES
  • TABLE 42. VERO BIOTECH LLC: COMPANY SNAPSHOT
  • TABLE 43. VERO BIOTECH LLC: PRODUCT SEGMENTS
  • TABLE 44. VERO BIOTECH LLC: PRODUCT PORTFOLIO
  • TABLE 45. SOL GROUP: KEY EXECUTIVES
  • TABLE 46. SOL GROUP: COMPANY SNAPSHOT
  • TABLE 47. SOL GROUP: PRODUCT SEGMENTS
  • TABLE 48. SOL GROUP: PRODUCT PORTFOLIO
  • TABLE 49. SOL GROUP: KEY STRATERGIES
  • TABLE 50. AIR WATER INC.: KEY EXECUTIVES
  • TABLE 51. AIR WATER INC.: COMPANY SNAPSHOT
  • TABLE 52. AIR WATER INC.: PRODUCT SEGMENTS
  • TABLE 53. AIR WATER INC.: PRODUCT PORTFOLIO
  • TABLE 54. CHEMIX SPECIALTY GASES AND EQUIPMENT: KEY EXECUTIVES
  • TABLE 55. CHEMIX SPECIALTY GASES AND EQUIPMENT: COMPANY SNAPSHOT
  • TABLE 56. CHEMIX SPECIALTY GASES AND EQUIPMENT: PRODUCT SEGMENTS
  • TABLE 57. CHEMIX SPECIALTY GASES AND EQUIPMENT: PRODUCT PORTFOLIO
  • TABLE 58. NIPPON SANSO HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 59. NIPPON SANSO HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 60. NIPPON SANSO HOLDINGS CORPORATION: PRODUCT SEGMENTS
  • TABLE 61. NIPPON SANSO HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 62. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: KEY EXECUTIVES
  • TABLE 63. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: COMPANY SNAPSHOT
  • TABLE 64. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: PRODUCT SEGMENTS
  • TABLE 65. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 66. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: KEY EXECUTIVES
  • TABLE 67. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: COMPANY SNAPSHOT
  • TABLE 68. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: PRODUCT SEGMENTS
  • TABLE 69. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. INHALED NITRIC OXIDE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF INHALED NITRIC OXIDE MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN INHALED NITRIC OXIDE MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN INHALED NITRIC OXIDE MARKET (2023-2032)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL INHALED NITRIC OXIDE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR ACUTE RESPIRATORY DISTRESS SYNDROME, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. INHALED NITRIC OXIDE MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 17. U.S. INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 18. CANADA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 19. MEXICO INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 20. GERMANY INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. FRANCE INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. UK INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. ITALY INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. REST OF EUROPE INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. JAPAN INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. AUSTRALIA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. REST OF ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. LATIN AMERICA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR (2020-2021)
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2021)
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY (2020-2021)
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: INHALED NITRIC OXIDE MARKET
  • FIGURE 36. TOP PLAYER POSITIONING, 2022
  • FIGURE 37. AIR LIQUIDE S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 38. AIR LIQUIDE S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 39. AIR LIQUIDE S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 40. LINDE PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 41. LINDE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 42. LINDE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 43. MALLINCKRODT PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. MALLINCKRODT PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 45. MALLINCKRODT PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. SOL GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. SOL GROUP: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. SOL GROUP: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. AIR WATER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. AIR WATER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. NIPPON SANSO HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. NIPPON SANSO HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
目次
Product Code: A02681

The global inhaled nitric oxide market was valued at $0.8 billion in 2022, and is projected to reach $1.6 billion by 2032, growing at a CAGR of 7.7% from 2023 to 2032

Inhaled nitric oxide is a therapeutic gas used to manage and treat hypoxic respiratory failure or persistent pulmonary hypertension in newborns. Inhaled nitric oxide is a selective pulmonary vasodilator, meaning it helps improve blood flow to well-ventilated areas of the lung, thus improving ventilation-perfusion matching and reducing pulmonary hypertension. The primary mechanism of action involves the activation of guanylate cyclase in smooth muscle cells, leading to an increase in cyclic guanosine monophosphate (cGMP) and subsequent vasodilation.

Inhaled Nitric Oxide Market - IMG1

The growth of the inhaled nitric oxide market is attributed to the high adoption of the inhaled nitric oxide for neonatal hypoxic respiratory failure and rise in prevalence of chronic obstructive pulmonary disease. The high adoption of inhaled nitric oxide for neonatal hypoxic respiratory failure stands out as a major driver propelling the growth of the inhaled nitric oxide market. In recent years, inhaled nitric oxide has emerged as a crucial therapeutic intervention in the neonatal care landscape, particularly for infants experiencing respiratory distress due to hypoxic conditions. For instance, the U.S. Food and Drug Administration has approved INOmax in 1999 and Genosyl in 2019 for term and near-term infants (>34 weeks' gestation) with hypoxic respiratory failure associated with clinical or echocardiographic signs of pulmonary hypertension to improve oxygenation and lower the risk of extracorporeal membrane oxygenation.

Neonates often face challenges in adapting to extrauterine life, and hypoxic respiratory failure is a critical concern during this transitional period. Inhaled nitric oxide, with its vasodilatory properties, acts selectively on the pulmonary vasculature, improving oxygenation by dilating the pulmonary vessels and reducing pulmonary hypertension. Its efficacy in enhancing oxygen delivery while minimizing potential systemic side effects has garnered widespread acceptance among healthcare professionals.

The increased prevalence of neonatal hypoxic respiratory failure, attributed to factors such as premature birth and congenital disorders, has led to a surge in the demand for effective treatment options, further driving the adoption of inhaled nitric oxide. Moreover, the growth in awareness among healthcare providers about the benefits of inhaled nitric oxide in preventing or mitigating hypoxic-induced complications has contributed to widespread incorporation of inhaled nitric oxide into neonatal intensive care protocols. Thus, the high adoption of the inhaled nitric oxide for neonatal hypoxic respiratory failure is expected to drive the growth of the inhaled nitric oxide.

Furthermore, rise in prevalence of chronic obstructive pulmonary disease is expected to drive the growth of the market. Chronic obstructive pulmonary disease, a progressive and debilitating respiratory condition primarily caused by prolonged exposure to harmful particles or gases, such as those found in cigarette smoke, is reaching alarming levels globally. For instance, according to the 2022 report by the National Library of Medicine, it was reported that chronic obstructive pulmonary disease (COPD) has a worldwide prevalence of 10.1% in people aged 40 years or older. As the incidence of COPD continues to rise, there is an urgent demand for effective therapeutic interventions that can alleviate the symptoms and enhance the overall quality of life for affected individuals. The adoption of inhaled nitric oxide has surged owing to its potential in managing respiratory disorders, including COPD. The vasodilatory and anti-inflammatory properties of nitric oxide make it a promising candidate for improving pulmonary function. Thus, the rise in the prevalence of chronic obstructive pulmonary disease is expected to contribute significantly to the growth of the market.

The inhaled nitric oxide market is segmented on the basis of application, and region. By application, the market is classified into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, and rest of Europe), Asia-Pacific (Japan, Australia, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Major key players that operate in the global inhaled nitric oxide market are Air Liquide S.A, Linde Plc, Mallinckrodt Plc, Vero Biotech LLC, Chemix Specialty Gases and Equipment, Air Water Inc, Sichuan Salman Chemical Products Co., Ltd, Linde PLC, SOL Group, Nippon Sanso Holdings Corporation and Chengdu Taiyu Industrial Gases Co., Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the inhaled nitric oxide market analysis from 2022 to 2032 to identify the prevailing inhaled nitric oxide market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the inhaled nitric oxide market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global inhaled nitric oxide market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Application

  • Neonatal Respiratory Treatment
  • Chronic Obstructive Pulmonary Disease
  • Acute Respiratory Distress Syndrome
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Air Liquide S.A.
    • Mallinckrodt plc
    • Chemix Specialty Gases and Equipment
    • Vero Biotech LLC
    • Air Water Inc.
    • Sichuan Salman Chemical Products Co., Ltd
    • Linde PLC
    • SOL Group
    • Nippon Sanso Holdings Corporation
    • Chengdu Taiyu Industrial Gases Co., Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. High adoption of the inhaled nitric oxide for management of pulmonary disorders in the infants and newborns.
      • 3.4.1.2. Rise in prevalence of the respiratory disorders.
      • 3.4.1.3. Advancements in healthcare infrastructure.
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of inhaled nitric oxide.
    • 3.4.3. Opportunities
      • 3.4.3.1. High research and development activities for inhaled nitric oxide.
  • 3.5. Market Share Analysis

CHAPTER 4: INHALED NITRIC OXIDE MARKET, BY APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Neonatal Respiratory Treatment
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic Obstructive Pulmonary Disease
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Acute Respiratory Distress Syndrome
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: INHALED NITRIC OXIDE MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Application
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Application
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Application
      • 5.2.3.3. Mexico
      • 5.2.3.3.1. Market size and forecast, by Application
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Application
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Application
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Application
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Application
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Application
      • 5.3.3.5. Rest of Europe
      • 5.3.3.5.1. Market size and forecast, by Application
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Application
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Application
      • 5.4.3.2. Australia
      • 5.4.3.2.1. Market size and forecast, by Application
      • 5.4.3.3. Rest of Asia-Pacific
      • 5.4.3.3.1. Market size and forecast, by Application
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Application
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Latin America
      • 5.5.3.1.1. Market size and forecast, by Application
      • 5.5.3.2. Middle East And Africa
      • 5.5.3.2.1. Market size and forecast, by Application

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2022

CHAPTER 7: COMPANY PROFILES

  • 7.1. Air Liquide S.A.
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
  • 7.2. Linde PLC
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
    • 7.2.7. Key strategic moves and developments
  • 7.3. Mallinckrodt plc
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Business performance
  • 7.4. Vero Biotech LLC
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
  • 7.5. SOL Group
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
    • 7.5.6. Business performance
    • 7.5.7. Key strategic moves and developments
  • 7.6. Air Water Inc.
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Business performance
  • 7.7. Chemix Specialty Gases and Equipment
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
  • 7.8. Nippon Sanso Holdings Corporation
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Business performance
  • 7.9. Chengdu Taiyu Industrial Gases Co., Ltd.
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
  • 7.10. Sichuan Salman Chemical Products Co., Ltd
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio